Allergy Therapeutics plc (FRA:HHU)

Market Cap	752.60M
Revenue (ttm)	67.30M
Net Income (ttm)	-43.11M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	16,344
Open	0.1030
Previous Close	0.1100
Day's Range	0.1030 - 0.1030
52-Week Range	0.0510 - 0.1250
Beta	n/a
RSI	70.92
Earnings Date	Nov 20, 2025

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to ad...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 612
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HHU

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.

Financial numbers in GBP